



## REFERENCES

- Adam, A.A.M., Abdullah, N.E., El Hassan, L.A.M., Elamin, E.M., Ibrahim, M.E., El Hassan, A.M., 2014. Detection of Epstein-Barr Virus in Nasopharyngeal Carcinoma in Sudanese by *in Situ* Hybridization. *Journal of Cancer Therapy* 05, 517–522. <https://doi.org/10.4236/jct.2014.56059>
- Glastonbury C. Nasopharyngeal carcinoma: the role of magnetic resonance imaging in diagnosis, staging, treatment, and follow-up. *Top Magn Reson Imaging* 2007; 18:225–235
- Dubrulle, F., Souillard, R. and Hermans, R. (2007). Extension patterns of nasopharyngeal carcinoma. *European Radiology*, 17(10), pp.2622-2630.
- Chin, S., Fatterpekar, G., Chen, C. and Som, P. (2003). MR Imaging of Diverse Manifestations of Nasopharyngeal Carcinomas. *American Journal of Roentgenology*, 180(6), pp.1715-1722.
- International Agency for Research and Cancer (1992). Cancer incidence in five continents. IARC
- International Agency for Research and Cancer (2003). World cancer report. IARC
- Spano, J., Busson, P., Atlan, D., Bourhis, J., Pignon, J., Esteban, C. and Armand, J. (2003). Nasopharyngeal carcinomas. *European Journal of Cancer*, 39(15), pp.2121-2135.



- Hildesheim, A. and Levine, P. (1993). Etiology of Nasopharyngeal Carcinoma: A Review. *Epidemiologic Reviews*, 15(2), pp.466-485.
- Lo, K., To, K. and Huang, D. (2004). Focus on nasopharyngeal carcinoma. *Cancer Cell*, 5(5), pp.423-428.
- International Agency for Research and Cancer (1997). Cancer incidence in five continents. IARC.
- King, A. (2010). Magnetic resonance imaging staging of nasopharyngeal carcinoma in the head and neck. *World Journal of Radiology*, 2(5), p.159.
- Chong, V. and Ong, C. (2008). Nasopharyngeal carcinoma. *European Journal of Radiology*, 66(3), pp.437-447.
- Jia, W., Huang, Q., Liao, J., Ye, W., Shugart, Y., Liu, Q., Chen, L., Li, Y., Lin, X., Wen, F., Adami, H., Zeng, Y. and Zeng, Y. (2006). Trends in incidence and mortality of nasopharyngeal carcinoma over a 20–25 year period (1978/1983–2002) in Sihui and Cangwu counties in southern China. *BMC Cancer*, 6(1).
- Parkin, D., Bray, F., Ferlay, J. and Pisani, P. (2005). Global Cancer Statistics, 2002. *CA: A Cancer Journal for Clinicians*, 55(2), pp.74-108.
- Jeannel, D., Bouvier, G., Hubert, A. (1999) Nasopharyngeal carcinoma: an epidemiological approach to carcinogenesis. *Cancer Surv*, 33:125-155.
- Weber, A., Al Arayedh, S. and Rashid, A. (2003). Nasopharynx. *Neuroimaging Clinics of North America*, 13(3), pp.465-483.
- Hutajulu, S., Indrasari, S., Indrawati, L., Harijadi, A., Duin, S., Haryana, S., Steenbergen, R., Greijer, A. and Middeldorp, J. (2011). Epigenetic markers



for early detection of nasopharyngeal carcinoma in a high risk population.

*Molecular Cancer*, 10(1), p.48.

Tao, Q. (2006). Epstein-Barr virus (EBV) and its associated human cancers - Genetics, epigenetics, pathobiology and novel therapeutics. *Frontiers in Bioscience*, 11(1), p.2672.

Yu, M. and Yuan, J. (2006). Nasopharyngeal Cancer. *Cancer Epidemiology and Prevention*, pp.620-626

Chiang, T. and Griem, M. (1973). Nasopharyngeal Cancer. *Surgical Clinics of North America*, 53(1), pp.121-133.

Yu, M., Ho, J., Ross, R. and Henderson, B. (1981). Nasopharyngeal carcinoma in Chinese—Salted fish or inhaled smoke?. *Preventive Medicine*, 10(1), pp.15-24.

Sriamporn, S., Vatanasapt, V., Pisani, P., Yongchaiyudha, S. and Rungpitarangsri, V. (1992). Environmental risk factors for nasopharyngeal carcinoma: a case-control study in northeastern Thailand. *Cancer Epidemiol Biomarkers Prev.*, 1(5), pp.345-8.

Jeannel, D., Hubert, A., De Vathaire, F., Ellouz, R., Camoun, M., Ben Salem, M., Sancho-Garnier, H. and De-Thé, G. (1990). Diet, living conditions and nasopharyngeal carcinoma in tunisia—a case-control study. *International Journal of Cancer*, 46(3), pp.421-425.

Wei, W. and Sham, J. (2005). Nasopharyngeal carcinoma. *The Lancet*, 365(9476), pp.2041-2054.



- Farrell, P. (2015). Epstein–Barr Virus Strain Variation. *Current Topics in Microbiology and Immunology*, pp.45-69.
- Knipe, D. and Howley, P. (2007). *Fields Virology*. 5th ed. Philadelphia: Wolters Kluwer.
- Sixbey, J. and Yao, Q. (1992). Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. *Science*, 255(5051), pp.1578-1580.
- Perri, F., Della Vittoria Scarpati, G., Giuliano, M., D’Aniello, C., Gnoni, A., Cavaliere, C., Licchetta, A. and Pisconti, S. (2015). Epstein–Barr virus infection and nasopharyngeal carcinoma. *Anti-Cancer Drugs*, 26(10), pp.1017-1025.
- Tsao, S., Tsang, C. and Lo, K. (2017). Epstein–Barr virus infection and nasopharyngeal carcinoma. *Philosophical Transactions of the Royal Society B: Biological Sciences*, 372(1732), p.20160270.
- Chan, K., Gu, Y., Ng, F., Ng, P., Seto, W., Sham, J., Chua, D., Wei, W., Chen, Y., Luk, W., Zong, Y. and Ng, M. (2003). EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. *International Journal of Cancer*, 105(5), pp.706-709.
- Zeng, Y., Jan, M., Zhang, Q., Zhang, L., Li, H., Wu, Y., Wang, Y. and Su, G. (1982). Serological mass survey for early detection of nasopharyngeal carcinoma in wuzhou city, china. *International Journal of Cancer*, 29(2), pp.139-141.
- Chien, Y., Chen, J., Liu, M., Yang, H., Hsu, M., Chen, C. and Yang, C. (2001). Serologic Markers of Epstein–Barr Virus Infection and Nasopharyngeal



- Carcinoma in Taiwanese Men. *New England Journal of Medicine*, 345(26), pp.1877-1882.
- Alfieri, C. (2006). Epstein-Barr Virus: Epstein-Barr Virus. *Clinical Infectious Diseases*, 43(5), pp.669-670.
- Deng, H., Y. Zeng, Y. Lei, Z. Zhao, P. Wang, B. Li, Z. Pi, B. Tan, Y. Zheng, W. Pan, et al. 1995. Serological survey of nasopharyngeal carcinoma in 21 cities of south China. *Chin. Med. J.* 108:300–303.
- Yu, X., Ji, M., Cheng, W., Wu, B., Du, Y. and Cao, S. (2018). Assessment of the Long-term Diagnostic Performance of a New Serological Screening Scheme in Large-scale Nasopharyngeal Carcinoma Screening. *Journal of Cancer*, 9(12), pp.2093-2097.
- Li, T., Guo, X., Ji, M., Li, F., Wang, H., Cheng, W., Chen, H., Ng, M., Ge, S., Yuan, Y. and Xia, N. (2018). Establishment and validation of a two-step screening scheme for improved performance of serological screening of nasopharyngeal carcinoma. *Cancer Medicine*, 7(4), pp.1458-1467.
- Ji, M., Wang, D., Yu, Y., Guo, Y., Liang, J., Cheng, W., Zong, Y., Chan, K., Ng, S., Wei, W., Chua, D., Sham, J. and Ng, M. (2007). Sustained elevation of Epstein–Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. *British Journal of Cancer*, 96(4), pp.623-630.
- Tosteson, A. N. A., Fryback, D. G., Hammond, C. S., Hanna, L. G., Grove, M. R., Brown, M., Wang, Q. F., Lindfors, K., Pisano, E. D., 2014. Consequences of False-Positive Screening Mammograms. *JAMA Intern Med.* 2014 June 1; 174(6): 954–961.



- Al-Sarraf, M., LeBlanc, M., Giri, P., Fu, K., Cooper, J., Vuong, T., Forastiere, A., Adams, G., Sakr, W., Schuller, D. and Ensley, J. (1998). Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. *Journal of Clinical Oncology*, 16(4), pp.1310-1317.
- Wagner, H., Hornef, M., Teichert, H. and Kirchner, H. (1994). Sex Difference in the Serostatus of Adults to the Epstein-Barr Virus. *Immunobiology*, 190(4-5), pp.424-429.
- Xie, S., Yu, I., Tse, L., Mang, O. and Yue, L. (2013). Sex difference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983–2008: Suggestion of a potential protective role of oestrogen. *European Journal of Cancer*, 49(1), pp.150-155.
- Hutajulu, S., Fachiroh, J., Argy, G., Indrasari, S., Indrawati, L., Paramita, D., Jati, T. and Middeldorp, J. (2017). Seroprevalence of IgA anti Epstein-Barr virus is high among family members of nasopharyngeal cancer patients and individuals presenting with chronic complaints in head and neck area. *PLOS ONE*, 12(8), p.e0180683.
- Guo, X., Johnson, R., Deng, H., Liao, J., Guan, L., Nelson, G., Tang, M., Zheng, Y., de The, G., O'Brien, S., Winkler, C. and Zeng, Y. (2009). Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. *International Journal of Cancer*, 124(12), pp.2942-2947.
- Soeripto. *Epidemiology of Nasopharyngeal Carcinoma*. Berita Kedokteran Masyarakat, 1998:207-211.



- Adham, M., Kurniawan, A.N., Muhtadi, A.I., Roezin, A., Hermani, B., Gondhowiardjo, S., Tan, I.B., Middeldorp, J.M., 2012. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. *Chinese Journal of Cancer* 31, 185–196.  
<https://doi.org/10.5732/cjc.011.10328>
- Ahn, Y. and Kim, Y. (2016). Korean perspectives of nasopharynx cancer management. *Chinese Clinical Oncology*, 5(2), pp.28-28.
- AJCC and ACOS, 2018. AJCC Cancer Staging Form Supplement.
- Amon, W. and Farrell, P. (2005). Reactivation of Epstein-Barr virus from latency. *Reviews in Medical Virology*, 15(3), pp.149-156.
- Arvin, A. (2007). *Human herpesviruses*. Cambridge: Cambridge Univ. Press.
- Badan Perencanaan Pembangunan Nasional (2013). *Proyeksi penduduk Indonesia, 2010-2035*. Jakarta: Badan Pusat Statistik, p.23.
- Cao, S., Simons, M. and Qian, C. (2011). The prevalence and prevention of nasopharyngeal carcinoma in China. *Chinese Journal of Cancer*, 30(2), pp.114-119.
- Chan, A.T.C., Teo, P.M.L., Huang, D.P., 2004a. Pathogenesis and treatment of nasopharyngeal carcinoma. *Seminars in Oncology* 31, 794–801.  
<https://doi.org/10.1053/j.seminoncol.2004.09.008>
- Cheng, Y., Chen, J., Glaser, R. and Henle, W. (1980). Frequency and levels of antibodies to Epstein-Barr virus-specific DNase are elevated in patients with nasopharyngeal carcinoma. *Proceedings of the National Academy of Sciences*, 77(10), p.6162.



Coghill, A. E., Hsu, W. L., Pfeiffer, R. M., Juwana, H., Yu, K. J., Lou, P. J., ...

Hildesheim, A. (2014). Epstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 23(7), 1213–1219. doi:10.1158/1055-9965.EPI-13-1262

Dardari, R., Menezes, J., Drouet, E., Joab, I., Benider, A., Bakkali, H., Kanouni, L., Jouhadi, H., Benjaafar, N., Gueddari, B., Hassar, M. and Khyatti, M. (2008). Analyses of the prognostic significance of the Epstein–Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma. *Journal of Clinical Virology*, 41(2), pp.96-103.

Deng, H., Y. Zeng, Y. Lei, Z. Zhao, P. Wang, B. Li, Z. Pi, B. Tan, Y. Zheng, W. Pan, et al. 1995. Serological survey of nasopharyngeal carcinoma in 21 cities of south China. *Chin. Med. J.* 108:300–303.

De Paschale, M., 2012. Serological diagnosis of Epstein-Barr virus infection: Problems and solutions. *World Journal of Virology* 1, 31. <https://doi.org/10.5501/wjv.v1.i1.31>

Dietz, P., Bombard, J., Mulready-Ward, C., Gauthier, J., Sackoff, J., Brozicevic, P., Gambatese, M., Nyland-Funke, M., England, L., Harrison, L. and Taylor, A. (2014). Validation of Self-reported Maternal and Infant Health



Indicators in the Pregnancy Risk Assessment Monitoring System. *Maternal and Child Health Journal*, 18(10), pp.2489-2498.

Draborg, A., Duus, K. and Houen, G. (2013). Epstein-Barr Virus in Systemic Autoimmune Diseases. *Clinical and Developmental Immunology*, [online] 2013. Available at:

[https://www.researchgate.net/publication/256985763\\_Epstein-Barr\\_Virus\\_in\\_Systemic\\_Autoimmune\\_Diseases](https://www.researchgate.net/publication/256985763_Epstein-Barr_Virus_in_Systemic_Autoimmune_Diseases) [Accessed 27 Aug. 2019].

Drake, R. L., Vogl, W., Mitchell, A. W. M., 2009. Gray's Anatomy for Students 2nd International Edition. Elsevier. ISBN 9780323286022

Fachiroh, J., Paramita, D.K., Hariwiyanto, B., Harijadi, A., Dahlia, H.L., Indrasari, S.R., Kusumo, H., Zeng, Y.S., Schouten, T., Mubarika, S., Middeldorp, J.M., 2006. Single-Assay Combination of Epstein-Barr Virus (EBV) EBNA1- and Viral Capsid Antigen-p18-Derived Synthetic Peptides for Measuring Anti-EBV Immunoglobulin G (IgG) and IgA Antibody Levels in Sera from Nasopharyngeal Carcinoma Patients: Options for Field Screening. *Journal of Clinical Microbiology* 44, 1459–1467. <https://doi.org/10.1128/JCM.44.4.1459-1467.2006>

Fachiroh, J., Schouten, T., Hariwiyanto, B., Paramita, D.K., Harijadi, A., Haryana, S.M., Ng, M.H., Middeldorp, J.M., 2004. Molecular Diversity of Epstein-Barr Virus IgG and IgA Antibody Responses in Nasopharyngeal Carcinoma: A Comparison of Indonesian, Chinese, and European Subjects. *The Journal of Infectious Diseases* 190, 53–62. <https://doi.org/10.1086/421245>



- Glastonbury, C.M., Salzman, K.L., 2013. Pitfalls in the Staging of Cancer of Nasopharyngeal Carcinoma. *Neuroimaging Clinics of North America* 23, 9–25. <https://doi.org/10.1016/j.nic.2012.08.006>
- Goudarzi, S., Ahmadi, A., Farhadi, M., Kamrava, S.K., Mobarrez, F., Omidfar, K., 2015. A new gold nanoparticle based rapid immunochromatographic assay for screening EBV-VCA specific IgA in nasopharyngeal carcinomas. *Journal of Applied Biomedicine* 13, 123–129. <https://doi.org/10.1016/j.jab.2014.08.001>
- Held, P. (2015). *Sample Preparation for Fluorescence Microscopy: An Introduction - Concepts and Tips for Better Fixed Sample Imaging Results*. [ebook] Winooski: BioTek Instruments, Inc. Available at: [https://www.biotek.com/assets/tech\\_resources/Cell%20Fixation%20White%20Paper.pdf](https://www.biotek.com/assets/tech_resources/Cell%20Fixation%20White%20Paper.pdf) [Accessed 12 May 2019].
- Herman, C. (2006). What Makes a Screening Exam "good"?. *AMA Journal of Ethics*, [online] 8(1), pp.34-37. Available at: <https://journalofethics.ama-assn.org/article/what-makes-screening-exam-good/2006-01> [Accessed 22 Oct. 2019].
- Hildesheim, A. and Wang, C. (2012). Genetic predisposition factors and nasopharyngeal carcinoma risk: A review of epidemiological association studies, 2000-2011. *Seminars in Cancer Biology*, 22(2), pp.107-116.
- Hulley, S., Cummings, S. and Browner, W. (2015). *Designing Clinical Research*. 4th ed. Philadelphia: Wolters Kluwer.



- Hutajulu, S., Fachiroh, J., Argy, G., Indrasari, S., Indrawati, L., Paramita, D., Jati, T. and Middeldorp, J. (2017). Seroprevalence of IgA anti Epstein-Barr virus is high among family members of nasopharyngeal cancer patients and individuals presenting with chronic complaints in head and neck area. *PLOS ONE*, 12(8), p.e0180683.
- Hu, T., Lin, C., Xie, S., Chen, G., Lu, Y., Ling, W., Huang, Q., Liu, Q. and Cao, S. (2019). Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epstein-Barr Virus: An analysis of a prospective study in southern China. *Cancer Medicine*, 8(5), pp.2561-2571.
- IARC (2012). *A review of human carcinogens*. Lyon, France: International Agency for Research on Cancer, p.50.
- Jia, W., Huang, Q., Liao, J., Ye, W., Shugart, Y., Liu, Q., Chen, L., Li, Y., Lin, X., Wen, F., Adami, H., Zeng, Y. and Zeng, Y. (2006). Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. *BMC Cancer*, 6(1).
- Ji, M., Wang, D., Yu, Y., Guo, Y., Liang, J., Cheng, W., Zong, Y., Chan, K., Ng, S., Wei, W., Chua, D., Sham, J. and Ng, M. (2007). Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. *British Journal of Cancer*, 96(4), pp.623-630.
- Canreg.fk.ugm.ac.id. (2018). *RKBR Oktober 2018 – canreg.fk.ugm.ac.id*. [online] Available at: <https://canreg.fk.ugm.ac.id/laporan-data/rkbr-oktober-2018/> [Accessed 27 Oct. 2019].



Kang, M., Long, J., Li, G., Yan, H., Feng, G., Liu, M., Zhu, J. and Wang, R.

(2016). A new staging system for nasopharyngeal carcinoma based on intensity-modulated radiation therapy: results of a prospective multicentric clinical study. *Oncotarget*, 7(12).

King, A., Vlantis, A., Yuen, T., Law, B., Bhatia, K., Zee, B., Woo, J., Chan, A.,

Chan, K. and Ahuja, A. (2015). Detection of Nasopharyngeal Carcinoma by MR Imaging: Diagnostic Accuracy of MRI Compared with Endoscopy and Endoscopic Biopsy Based on Long-Term Follow-Up. *American Journal of Neuroradiology*, 36(12), pp.2380-2385.

Komite Penanggulangan Kanker Nasional (2017). *Panduan Penatalaksanaan*

*Kanker Nasofaring*. [ebook] Kementerian Kesehatan Republik Indonesia.

Available at:

<http://www.kanker.kemkes.go.id/guidelines/PPKNasofaring.pdf> [Accessed 12 Feb. 2019].

Kumar, V., Abbas, A., Aster, J., Robbins, S., Cornain, S. and Nasar, I. (2015).

*Buku ajar patologi Robbins*. 9th ed. Singapore: Elsevier.

Li, X., Fasano, R., Wang, E., Yao, K.-T., Marincola, F.M., 2009. HLA

associations with nasopharyngeal carcinoma. *Curr. Mol. Med.* 9, 751–765.

Paramita, D.K., 2010. Diagnostic and protective aspects of humoral immune

responses to Epstein-Barr virus encoded proteins in nasopharyngeal carcinoma. s.n.], S.l.

Paramita, D.K., Fachiroh, J., Haryana, S.M., Middeldorp, J.M., 2009. Two-Step

Epstein-Barr Virus Immunoglobulin A Enzyme-Linked Immunosorbent



- Assay System for Serological Screening and Confirmation of Nasopharyngeal Carcinoma. *Clinical and Vaccine Immunology* 16, 706–711. <https://doi.org/10.1128/CVI.00425-08>
- Razek, A.A.K.A., King, A., 2012. MRI and CT of Nasopharyngeal Carcinoma. *American Journal of Roentgenology* 198, 11–18. <https://doi.org/10.2214/AJR.11.6954>
- Romesser, P. B., Riaz, N., Ho, A. L., Wong, R. J. And Lee, N. Y. (2013) ‘Cancers of Head and Neck’ in Niederhuber, J., Armitage, J., Doroshow, J., Kastan, M. and Tepper, J. (2014). *Abeloff's clinical oncology*. 5th ed. Philadelphia: Saunders.
- Tay, J., Lim, M. and Kanagalingam, J. (2014). Screening in Nasopharyngeal Carcinoma: Current Strategies and Future Directions. *Current Otorhinolaryngology Reports*, 2(1), pp.1-7.
- VIRapid Mono M&G: The complete diagnostic tool for EBV infectious mononucleosis. (2019). [ebook] Granada. Available at: [https://en.vircell.com/media/filer\\_public/ec/af/ecafc218-539e-48a9-ada8-0ec641165710/virapid\\_mono\\_en.pdf](https://en.vircell.com/media/filer_public/ec/af/ecafc218-539e-48a9-ada8-0ec641165710/virapid_mono_en.pdf) [Accessed 19 Sep. 2019].
- Wan, T. (2008). *C.I. Calculator for Diagnostic Statistics*. [online] [www2.ccrb.cuhk.edu.hk](http://www2.ccrb.cuhk.edu.hk). Available at: <https://www2.ccrb.cuhk.edu.hk/stat/confidence%20interval/Diagnostic%20Statistic.htm> [Accessed 26 Aug. 2019].



- Woellmer, A., Hammerschmidt, W., 2013. Epstein-Barr virus and host cell methylation: regulation of latency, replication and virus reactivation. *Curr Opin Virol* 3, 260–265. <https://doi.org/10.1016/j.coviro.2013.03.005>
- Xia, C., Zhu, K., Zheng, G., 2015. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis. *Int J Clin Exp Pathol* 8, 16104–16110.
- Yu, M. and Yuan, J. (2002). Epidemiology of nasopharyngeal carcinoma. *Seminars in Cancer Biology*, 12(6), pp.421-429.